Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONStandard

TYVASO DPI

TREPROSTINIL

Standard Dose
0.032MG/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview TYVASO DPI is listed in Drugs@FDA under application 214324 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient TREPROSTINIL Form and strength POWDER;INHALATION - 0.032MG/INH Sponsor UNITED THERAP Submission history Latest submission status date: 2022-05-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview TYVASO DPI is listed in Drugs@FDA under application 214324 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient TREPROSTINIL Form and strength POWDER;INHALATION - 0.032MG/INH Sponsor UNITED THERAP Submission history Latest submission status date: 2022-05-23 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.